Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Accured Expenses (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Change in Accured Expenses for 3 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 338.41% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 403.95% increase, with the full-year FY2025 number at $2.0 million, up 403.95% from a year prior.
  • Change in Accured Expenses was $2.4 million for Q4 2025 at Artiva Biotherapeutics, up from $1.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.1 million in Q3 2024 to a low of -$3.0 million in Q1 2024.
  • A 3-year average of $165222.2 and a median of $143000.0 in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: plummeted 793.71% in 2024, then soared 338.41% in 2025.
  • Artiva Biotherapeutics' Change in Accured Expenses stood at $143000.0 in 2023, then tumbled by 793.71% to -$992000.0 in 2024, then skyrocketed by 338.41% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Change in Accured Expenses are $2.4 million (Q4 2025), $1.1 million (Q3 2025), and -$550000.0 (Q2 2025).